<DOC>
	<DOCNO>NCT02200081</DOCNO>
	<brief_summary>Evaluation efficacy safety MGN1703 administer twice weekly subcutaneously ( SC ) maintenance treatment patient extensive disease small cell lung cancer ( SCLC ) achieve least partial response ( PR ) follow platinum-based first-line therapy .</brief_summary>
	<brief_title>Randomized Study Maintenance Therapy With MGN1703 Patients With SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Male female patient extensive disease SCLC ≥ 18 year age receive first line treatment ; 2 . Histology SCLC mixed histology SCLC SCLC histology least 80 % ; 3 . Completion 4 cycle firstline therapy platinumbased regimen prior chemotherapy ; 4 . Documented evidence tumor response assess investigator first 2 cycle platinumbased chemotherapy follow confirmed PR CR end fourth cycle CT MRI scan ; 5 . Brain metastasis allow cranial irradiation , require continuous treatment steroid anticonvulsant ; 6 . ECOG performance status 0 1 ; 7 . Adequate organ function total bilirubin , lactate dehydrogenase [ LDH ] , alkaline phosphatase [ AP ] , gamma glutamyltransferase [ GGT ] , albumin , creatinine , urea , electrolyte , coagulation parameter ≤ 1.5 × upper limit normal ( ULN ) , aspartate aminotransferase [ AST ] ALT ≤ 2.5 × ULN absence liver metastases ≤ 5.0 × ULN presence liver metastases ; 8 . Adequate hematological parameter : absolute neutrophil count ≥ 1.5 × 109/L ; platelet count ≥ 100 × 109/L ; leukocyte count ≥ 3.0 × 109/L ; lymphocyte ≥ 1.0 × 109/L ; hemoglobin ≥ 9.0 g/dL 5.59 mmol/L ; 9 . Patients reproductive potential agree use effective contraceptive measure throughout study ; 10 . Negative pregnancy test woman childbearing potential ; 11 . Signed informed consent form ( ICF ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extensive disease</keyword>
	<keyword>After first line therapy</keyword>
	<keyword>Immuno therapy</keyword>
</DOC>